Related Experiment Video
Updated: Feb 18, 2026

Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Validating cancer drug targets through chemical genetics
Mark E Burkard1, Prasad V Jallepalli
1University of Wisconsin Carbone Cancer Center and Department of Medicine, University of Wisconsin, Madison, WI 53792, USA. mburkard@wisc.edu
Abstract:
Targeted therapies for cancer promise to revolutionize treatment by specifically inactivating pathways needed for the growth of tumor cells. The most prominent example of such therapy is imatinib (Gleevec), which targets the BCR-ABL kinase and provides an effective low-toxicity treatment for chronic myelogenous leukemia. This success has spawned myriad efforts to develop similarly targeted drugs for other cancers. Unfortunately, the high expectations of these efforts have not yet been realized, likely due to the genetic diversity among and within tumors, as well as the complex and largely unpredictable interactions of drug-like compounds with innumerable targets that affect cellular and organismal metabolism. While improvements in sequencing technologies are beginning to address the first problem, solving the second problem requires methods for linking specific features of the cancer genome to their optimally targeted therapies. One approach, referred to as chemical genetics, accomplishes this by genetic control of chemical susceptibility. Chemical genetics is a crucial tool for the rational development of cancer drugs.
Insights
Targeted cancer therapies aim to inhibit tumor growth. Chemical genetics offers a way to link cancer genome features to effective drug treatments, advancing rational cancer drug development.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- Targeted cancer therapies, like imatinib for chronic myelogenous leukemia, show promise but face challenges due to tumor genetic diversity and complex drug interactions.
- Despite advances in sequencing, linking specific cancer genomic features to optimal therapies remains a significant hurdle.
Purpose of the Study:
- To explore chemical genetics as a method for rational cancer drug development.
- To address the challenge of matching targeted therapies to specific cancer genomic profiles.
Main Methods:
- Utilizing chemical genetics to establish a link between genetic makeup and drug response.
- Investigating methods for connecting specific cancer genome features to targeted therapies.
Main Results:
- Chemical genetics provides a framework for understanding drug susceptibility based on genetic alterations.
- This approach facilitates the rational design and selection of cancer therapies.
Conclusions:
- Chemical genetics is a vital tool for advancing targeted cancer therapy development.
- Overcoming tumor genetic complexity requires innovative approaches like chemical genetics to optimize treatment strategies.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Drug Discovery: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

